Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Genomics firm Sema4 to build lab in Stamford

Genomics-testing firm Sema4 is set to start construction on a 70,000-square-foot lab in the city’s Waterside section, a project that will more than double the...

| By Bill Kelly

UConn researchers record cell communication

Researchers with the University of Connecticut (UConn) School of Dental Medicine developed a technology platform that allows them to record cells communicating in real time....

| By Bill Kelly

SpringWorks in multiple myeloma collaboration

SpringWorks Therapeutics reports that the company has entered into a clinical trial collaboration agreement with GlaxoSmithKline to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination...

| By Bill Kelly

Yale researchers investigate metastasis

Yale researchers have discovered how metastasis, or the spread of cancer cells, is triggered on the molecular level. They also developed a way to detect those...

| By Bill Kelly

IsoPlexis receives $4 million grant re IsoLIght

IsoPlexis has received $4 million in grant funding from the National Cancer Institute’s Small Business Innovation Research Development Center as a part of the commercialization...

| By Bill Kelly

Tangen Biosciences closes $9 million Series A

Tangen Biosciences has closed a $9 million Series A equity round led by Connecticut Innovations (CI), with participation of current and new stockholders, including VC23, Axiom,...

| By Bill Kelly

FDA clears Arvinas breast cancer treatment

Arvinas reports that the FDA has cleared the company’s Investigational New Drug application for ARV-471, an oral estrogen receptor PROTAC® protein degrader, designed for treatment of...

| By Bill Kelly

UConn taps into cell communication

A new technology discovered by a team including UConn School of Dental Medicine researchers records cellular communication in real time – providing a closer look...

| By Bill Kelly

Intensity Therapeutics to collaborate with Merck

Intensity Therapeutics reports it has entered into an agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the...